News

BioTesserae Inc. (BTC), a biotechnology company focused on innovative veterinary therapeutics, in collaboration with Sunflower Therapeutics PBC, a public benefit corporation transforming global access to protein manufacturing capacity for diverse applications, today announced that BTC-001 was well tolerated in healthy dogs following a single ascending dose study. BTC-001 is a single domain antibody (SdA) that recognizes the immune checkpoint inhibitor PD-1 and is part of BioTesserae’s growing portfolio of biologic drugs for the treatment of cancer in companion animals.

In the face of unpredictable global market pressures, broad product pipelines, expectations for rapid profits, and the need for low-cost protein products, a rapid shift is taking place in the biotechnology industry from large-scale, single-product facilities to agile, distributed, and flexible manufacturing strategies.

In this Q&A, Dr. Love opens up about the challenges of modern biologics manufacturing, the real-world impact of Sunflower’s technologies, and how distributed, automated solutions are changing the game for global healthcare, food science, and beyond.

The Pharmaceutical Technology® Group spoke with Kerry Love, co-founder and CEO of Sunflower® Therapeutics at INTERPHEX 2025, to find out how automation enhances the manufacture of proteins.

The growing development of new biotherapeutic modalities will rely heavily on automation and progressive technologies.

Kerry Love co-founded Sunflower Therapeutics, where she now serves as CEO and president. She shares her journey with BioPharmaReporter.

As Director of R&D at Sunflower Therapeutics, Laura Crowell works with a team developing biologic medicines and vaccines. She sits down with BioPharma-Reporter to share her journey.

Alex Bonnyman is transforming protein manufacturing while championing women in STEM. Explore her journey of innovation, resilience, and inclusivity in biotechnology.